These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1976212)

  • 41. [Therapeutic applications of somatostatin and its analog, octreotide].
    Harris AG; Kokoris SP
    Presse Med; 1993 Apr; 22(15):724-33. PubMed ID: 8099737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vasoactive substances in early dumping syndrome: effects of dumping provocation with and without octreotide.
    Vecht J; Gielkens HA; Frölich M; Lamers CB; Masclee AA
    Eur J Clin Invest; 1997 Aug; 27(8):680-4. PubMed ID: 9279532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders.
    Dhar A; Chawla YK
    Trop Gastroenterol; 1995; 16(3):3-7. PubMed ID: 8838035
    [No Abstract]   [Full Text] [Related]  

  • 44. [Use of somatostatin in gastroenterology].
    Lamers CB
    Ned Tijdschr Geneeskd; 1986 May; 130(20):908-11. PubMed ID: 2873515
    [No Abstract]   [Full Text] [Related]  

  • 45. Somatostatin analog treatment of pancreatic fistulas.
    Barnes SM; Kontny BG; Prinz RA
    Int J Pancreatol; 1993 Oct; 14(2):181-8. PubMed ID: 8283081
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatostatin and the gastrointestinal tract.
    Tulassay Z
    Scand J Gastroenterol Suppl; 1998; 228():115-21. PubMed ID: 9867121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome.
    Hasler WL; Soudah HC; Owyang C
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1359-65. PubMed ID: 8667198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatostatin and post-gastrectomy dumping.
    Thirlby RC
    Gastroenterology; 1989 Nov; 97(5):1344. PubMed ID: 2676687
    [No Abstract]   [Full Text] [Related]  

  • 49. Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome.
    Wauters L; Vanuytsel T
    Curr Opin Pharmacol; 2018 Dec; 43():118-123. PubMed ID: 30273889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery.
    Bassi C; Falconi M; Pederzoli P
    Gut; 1994; 35(3 Suppl):S20-2. PubMed ID: 7911443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conservative management of pediatric pancreatic pseudocyst using octreotide acetate.
    Mulligan C; Howell C; Hatley R; Martindale R; Clark J
    Am Surg; 1995 Mar; 61(3):206-9. PubMed ID: 7887530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic value of octreotide for patients with severe dumping syndrome--a review of randomised controlled trials.
    Li-Ling J; Irving M
    Postgrad Med J; 2001 Jul; 77(909):441-2. PubMed ID: 11423592
    [No Abstract]   [Full Text] [Related]  

  • 53. Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure?
    Martineau P; Shwed JA; Denis R
    Am J Surg; 1996 Oct; 172(4):386-95. PubMed ID: 8873537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Future medical prospects for Sandostatin.
    Harris AG
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():55-60. PubMed ID: 1980778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sandostatin in the management of nonendocrine gastrointestinal and pancreatic disorders: a preliminary study.
    Rosenberg L; Brown RA
    Can J Surg; 1991 Jun; 34(3):223-9. PubMed ID: 2054754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Somatostatin in the treatment of pancreatic diseases].
    Németh AM
    Orv Hetil; 2002 May; 143(19 Suppl):1099-108. PubMed ID: 12063869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases].
    Feu F; Bosch J
    Gastroenterol Hepatol; 1996 Feb; 19(2):68-77. PubMed ID: 8616683
    [No Abstract]   [Full Text] [Related]  

  • 58. Emerging indications for octreotide therapy, Part 2.
    Mosdell KW; Visconti JA
    Am J Hosp Pharm; 1994 May; 51(10):1317-30. PubMed ID: 8085570
    [No Abstract]   [Full Text] [Related]  

  • 59. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
    Battershill PE; Clissold SP
    Drugs; 1989 Nov; 38(5):658-702. PubMed ID: 2689136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.